CPA1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL393002	1.00	9/20
SCHEMBL598436	0.54	8/20
SCHEMBL598437	0.54	8/20
SCHEMBL839261	0.68	7/20
SCHEMBL839262	0.68	7/20
SCHEMBL265063	0.66	7/20
SCHEMBL265514	0.66	7/20
SCHEMBL491524	0.66	7/20
SCHEMBL558159	0.66	7/20
SCHEMBL162841	0.61	7/20
SCHEMBL252900	0.59	7/20
SCHEMBL629350	0.59	7/20
SCHEMBL838961	0.56	7/20
SCHEMBL838962	0.56	7/20
SCHEMBL236628	0.55	7/20
SCHEMBL714764	0.53	7/20
Mitiglinide (SCHEMBL49085)	0.53	7/20
Mitiglinide (SCHEMBL676865)	0.53	7/20
Mitiglinide (SCHEMBL876930)	0.53	7/20
Mitiglinide (SCHEMBL305840)	0.51	7/20

Clinical trials — most relevant to CPA1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function	PHASE4	COMPLETED
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency	PHASE3	COMPLETED
A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema	PHASE3	COMPLETED
Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency	PHASE2/PHASE3	COMPLETED
Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema	PHASE2/PHASE3	WITHDRAWN
Berinert P Study of Subcutaneous Versus Intravenous Administration	PHASE3	COMPLETED
International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema	PHASE2/PHASE3	COMPLETED
A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema	PHASE3	COMPLETED
Effects of Anti-TSLP in Patients With Asthma	PHASE2	COMPLETED
Comparative Clinical Study to Evaluate the Possible Efficacy and Safety of Oral N-Acetyl Cysteine Versus Rectal Diclofenac in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis	PHASE1/PHASE2	COMPLETED
Chemokine Mechanisms in Chronic Pelvic Pain	nan	COMPLETED
Genetic Determinism of Epithelial Barrier Defects in Irritable Bowel Syndrome	nan	WITHDRAWN
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD)	nan	COMPLETED
Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests	nan	UNKNOWN
Markers in Acute Pancreatitis-1	nan	COMPLETED
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease	nan	ACTIVE_NOT_RECRUITING
Paraoxonase and LDL Oxidation in Carotid Artery Disease	nan	COMPLETED
Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers: The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3	nan	COMPLETED
Acute Pancreatitis Targets (APT) Study	nan	COMPLETED
Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals	nan	COMPLETED
Genomic Research in Alpha-1 Antitrypsin Deficiency	nan	COMPLETED
Disorders of the Acute Phase Response Following Trauma and Invasive Surgery	nan	ENROLLING_BY_INVITATION
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis	nan	COMPLETED
Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC)	nan	UNKNOWN
Proteomics of Primary Hyperoxaluria Type 1	nan	COMPLETED
Genetic Architecture of Plasma T-PA and PAI-1	nan	COMPLETED
The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations	nan	COMPLETED
Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous Xanthomatosis	nan	UNKNOWN
Cause and Natural Course of Pediatric-Onset Mastocytosis	nan	COMPLETED
PiMZ Longitudinal Cohort (PiMZ Logic)	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CPA1 binder may also engage these)

Protein	Name	Similarity
P09954	—	1.000	P09954 →
P00730	—	1.000	P00730 →
P00731	—	1.000	P00731 →
CPA2	Carboxypeptidase A2	1.000	landscape →
CPB1	Carboxypeptidase B	1.000	landscape →
P00732	—	1.000	P00732 →
P19223	—	1.000	P19223 →
P09955	—	1.000	P09955 →
Q8WXQ8	—	0.999	Q8WXQ8 →
Q7TPZ8	—	0.998	Q7TPZ8 →
Q504N0	—	0.997	Q504N0 →
P55261	—	0.997	P55261 →
P19222	—	0.993	P19222 →
CPA4	Carboxypeptidase A4	0.993	landscape →
Q6P8K8	—	0.993	Q6P8K8 →
A0A1S4F020	—	0.992	A0A1S4F020 →
Q29NC4	—	0.990	Q29NC4 →
Q4R7R2	—	0.990	Q4R7R2 →
Q8R4H4	—	0.989	Q8R4H4 →
Q9VL86	—	0.988	Q9VL86 →
Q3T905	—	0.988	Q3T905 →
Q9EQV9	—	0.988	Q9EQV9 →
C5FH26	—	0.988	C5FH26 →
D4D675	—	0.987	D4D675 →
O02350	—	0.987	O02350 →
Q8IVL8	—	0.986	Q8IVL8 →
D4DL57	—	0.986	D4DL57 →
C5FVN6	—	0.986	C5FVN6 →
B8JLQ9	—	0.986	B8JLQ9 →
B8XGR3	—	0.986	B8XGR3 →